XS228

· XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for XS228, covering 2025-11-25 to 2025-11-25. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial [Phase 1]

See pricing